Despite the market volatility, shares in Adverum Biotechnologies Inc (NMQ:ADVM) have been in an uptrend in recent months. The question now for investors is whether that price strength will continue. Finding stocks with the potential to...
ADVM — Adverum Biotechnologies Share Price
0.000.00%
Last Trade - 00:00HealthcareSpeculativeSmall CapSucker Stock
- $226.67m
- -$137.17m
- $7.50m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.46 | 1.85 | 1.61 | 0.25 | n/a | 6 | 1.07 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for ADVM
Ever since the 1980s, when the now-infamous "Turtle Traders" beat the market with simple strategies based on breakouts to new high prices, momentum investing has been shown to be a very profitable strategy. In fact, many academics now...
Profile Summary
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. The Company is evaluating its gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. It has collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products (AVA-311) for ophthalmic diseases. The Company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its capabilities include clinical development, vector discovery, and in-house manufacturing, specifically in process development, assay development and current Good Manufacturing Practices (cGMP) quality control.
Directors
- Patrick Machado NEC (57)
- Leone Patterson PRE (58)
- Laurent Fischer (57)
- Angela Thedinga (39)
- Brigit Riley
- Julie Clark
- Christopher DeRespino
- Peter Soparkar (50)
- Mehdi Gasmi DRC (54)
- Mark Lupher (50)
- James Scopa (62)
- Dawn Svoronos (67)
- Reed Tuckson (70)
- Scott Whitcup (61)
- Thomas Woiwode (49)
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- July 17th, 2006
- Public Since
- July 31st, 2014
- No. of Shareholders
- 15
- No. of Employees
- 167
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 98,125,866
- Address
- 800 Saginaw Drive, REDWOOD CITY, 94063
- Web
- https://adverum.com/
- Phone
- +1 6502726269
- Contact
- Amy Figueroa
- Auditors
- Ernst & Young LLP
Latest News for ADVM
Upcoming events for ADVM
Q3 2021 Adverum Biotechnologies Inc Earnings Release
Similar to ADVM
4D PHARMA ADR REP 8 ORD
NASDAQ Global Market
89BIO ORD
NASDAQ Global Market
ACCELERON PHARMA ORD
NASDAQ Global Market
ACELRX PHARMACEUTICALS ORD
NASDAQ Global Market
ADAGENE 4 ADR REP 5 ORD
NASDAQ Global Market
FAQ
What is the Adverum Biotechnologies share price?
As of Today at 19:56 UTC, shares in Adverum Biotechnologies are trading at $2.31. This share price information is delayed by 15 minutes.
How has the Adverum Biotechnologies share price performed this year?
Shares in Adverum Biotechnologies last closed at $2.31 and the price had moved by -83.14% over the past 365 days. In terms of relative price strength the Adverum Biotechnologies share price has underperformed the S&P500 Index by -87.21% over the past year.
What are the analyst and broker recommendations for Adverum Biotechnologies?
The overall consensus recommendation for Adverum Biotechnologies is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Adverum Biotechnologies dividend yield?
Adverum Biotechnologies does not currently pay a dividend.
Does Adverum Biotechnologies pay a dividend?
Adverum Biotechnologies does not currently pay a dividend.
When does Adverum Biotechnologies next pay dividends?
Adverum Biotechnologies does not currently pay a dividend.
How do I buy Adverum Biotechnologies shares?
To buy shares in Adverum Biotechnologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Adverum Biotechnologies?
As of the previous close price of $2.31, shares in Adverum Biotechnologies had a market capitalisation of $226.67m.
Where are Adverum Biotechnologies shares listed?
Here are the trading details for Adverum Biotechnologies:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ADVM
What kind of share is Adverum Biotechnologies?
Based on an overall assessment of its quality, value and momentum Adverum Biotechnologies is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Adverum Biotechnologies share price forecast for 2021?
The analyst consensus target price for shares in Adverum Biotechnologies is $3.88. That is 67.97% above the last closing price of $2.31.
Analysts covering Adverum Biotechnologies currently have a consensus Earnings Per Share (EPS) forecast of -$1.54 for the next financial year.
What is the trend in the Adverum Biotechnologies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adverum Biotechnologies. Over the past six months, its share price has underperformed the S&P500 Index by -84.27%.
As of the last closing price of $2.31, shares in Adverum Biotechnologies were trading -73.07% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Adverum Biotechnologies PE Ratio?
We are not able to find PE ratio data for Adverum Biotechnologies.
Who are the key directors of Adverum Biotechnologies?
Adverum Biotechnologies' management team is headed by:
- Patrick Machado - NEC
- Leone Patterson - PRE
- Laurent Fischer -
- Angela Thedinga -
- Brigit Riley -
- Julie Clark -
- Christopher DeRespino -
- Peter Soparkar -
- Mehdi Gasmi - DRC
- Mark Lupher -
- James Scopa -
- Dawn Svoronos -
- Reed Tuckson -
- Scott Whitcup -
- Thomas Woiwode -
Who are the major shareholders of Adverum Biotechnologies?
We do not have data on Adverum Biotechnologies' shareholders